trending Market Intelligence /marketintelligence/en/news-insights/trending/dmgyeoDePhY5EZ2GlSfT5w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BioXcel Therapeutics' acute agitation treatment gets US FDA fast-track status

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


BioXcel Therapeutics' acute agitation treatment gets US FDA fast-track status

BioXcel Therapeutics Inc.'s BXCL501 has been granted fast-track designation by the U.S. Food and Drug Administration to treat irritability and restlessness due to medical and psychiatric conditions.

BXCL501 is BioXcel Therapeutics' proprietary film of dexmedetomidine that is placed under the tongue to treat acute agitation. Patients with severe acute agitation are unable to control their behavior.

The FDA's fast-track status facilitates the development and expedites review of new drugs and vaccines that have a potential to fulfill an unmet medical need.

BioXcel Therapeutics expects topline results from its phase 1 study of BXCL501, which is evaluating the safety and absorption of the drug, in the first half of 2019.

New Haven, Conn.-based BioXcel Therapeutics develops novel drugs using intelligence and is working to identifying the next wave of medicines across neuroscience and immuno-oncology.